Key result
IABP and immunomodulatory therapy stabilize a patient with COVID-19-induced fulminant myocarditis and myositis.
Case Report (n=1)
COVID-19 infection can be complicated by severe fulminant myocarditis and myositis requiring mechanical circulatory support and immunomodulatory therapy.
May inform management of rare fulminant myocarditis; hypothesis-generating and requires prospective validation before practice change.
Herein, we report the case of a young female patient who suffered from myositis and heart failure due to fulminant myocarditis induced by the 2019 coronavirus disease (COVID-19). After receiving intra-aortic balloon pump (IABP) and immunomodulatory treatment, her vital signs gradually stabilized and the IABP was removed. Cardiac and muscle magnetic resonance imaging confirmed extensive myocardial and skeletal muscle edema. Though it is not uncommon for COVID-19 infection to be complicated by myocarditis and myositis, such serious muscle injury warrants clinical vigilance.
No takes yet. Share an insight, caveat, or question.
Miao et al. (2023) conducted a case report in COVID-19 induced fulminant myocarditis and myositis (n=1). Intra-aortic balloon pump (IABP) and immunomodulatory treatment was evaluated on Clinical stabilization. Intra-aortic balloon pump and immunomodulatory treatment stabilized a young female patient with COVID-19-induced fulminant myocarditis and myositis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: